When does Molecular Partners report earnings and why does it matter for MOLN.SW stock?

Earnings are scheduled after market close on 12 Mar 2026. The report matters because updates on clinical trials, partner milestones, and cash guidance will influence MOLN.SW stock volatility and near-term funding needs.

What is Meyka AI's price forecast for MOLN.SW stock?

Meyka AI's forecast model projects yearly **CHF 2.35**, monthly **CHF 2.97**, and quarterly **CHF 2.64**. These projections imply downside versus the current price and are model-based, not guarantees.

What are the main valuation metrics for Molecular Partners?

Key metrics: price **CHF 3.75**, EPS **-1.62**, PE **-2.31**, cash per share **2.79**, book value per share **2.55**, and market cap **CHF 140,246,820.00**. These show a capital-intensive, pre-revenue profile.

What should traders watch in the earnings release for MOLN.SW stock?

Watch R&D timelines, cash runway, partner milestone payments, and any regulatory or trial-readout dates. Positive partner news can outperform sector peers and lift MOLN.SW stock quickly.

CH Stocks

MOLN.SW Molecular Partners AG (SIX) CHF 3.75 pre-earnings 11 Mar 2026: key metrics

ByHuzaifa Zahoor March 11, 2026March 11, 2026

MOLN.SW stock is trading at CHF 3.75 intraday on SIX on 11 Mar 2026 as investors position ahead of Molecular Partners AG’s earnings report due 12 Mar 2026. Volume sits at 15,019.00 shares versus a 50-day average of 22,236.00, and the stock is up 2.60% today. Key numbers to watch are EPS -1.62 and a negative PE of -2.31, which underline the clinical-stage firm’s loss-making profile as clinical readouts and partner updates will drive the print. We use Meyka AI-powered market analysis to map scenarios and price targets.